IDEAYA Biosciences (NASDAQ: IDYA) revenue
IDEAYA Biosciences reported revenue of $218.7m for fiscal 2025, 3,024.4% more than in fiscal 2024 ($7.0m).
Fiscal 2025 is the highest of the 7 fiscal years on record for IDEAYA Biosciences. The biggest drop was in fiscal 2024, −70.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $218.7m | +3,024.4% | −$159.3m | −72.8% |
| 2024 | $7.0m | −70.1% | −$327.0m | −4,671.1% |
| 2023 | $23.4m | −54.1% | −$134.4m | −574.9% |
| 2022 | $50.9m | +82.3% | −$62.5m | −122.7% |
| 2021 | $27.9m | +43.0% | −$50.3m | −179.9% |
| 2020 | $19.5m | — | −$35.3m | −180.9% |
| 2019 | $0.0m | — | −$44.3m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
IDEAYA Biosciences revenue compared with its sector
By revenue for its latest fiscal year, IDEAYA Biosciences ranks 244th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; IDEAYA Biosciences, 3,024.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 242nd | Puma Biotechnology | $228.4m | −0.9% |
| 243rd | Axogen | $225.2m | 20.2% |
| 244th | IDEAYA Biosciences | $218.7m | 3,024.4% |
| 245th | Vanda Pharmaceuticals | $216.1m | 8.7% |
| 246th | Establishment Labs | $211.1m | 27.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of IDEAYA Biosciences
- How much revenue did IDEAYA Biosciences make in fiscal 2025?
- IDEAYA Biosciences reported revenue of $218.7m for fiscal 2025, compared with $7.0m in fiscal 2024.
- What was the best year for revenue at IDEAYA Biosciences?
- Of its last 7 fiscal years, fiscal 2025, with $218.7m.
- Where does IDEAYA Biosciences rank in its sector by revenue?
- It ranks 244th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for IDEAYA Biosciences come from?
- From the annual report (Form 10-K) that IDEAYA Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that IDEAYA Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on IDEAYA Biosciences: the IDEAYA Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.